The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
Abstract
The "catecholamine hypothesis of affective disorders" proposes that some, if not all, depressions are associated with an absolute or relative decrease in catecholamines, particularly norepinephrine, available at central adrenergic receptor sites. Elation, conversely, may be associated with an excess of such amines. Evidence supporting this hypothesis was reviewed. Data from pharmacological studies, mainly in animals, suggest that the actions of both major classes of antidepressant drugs are mediated through the catecholamines. The monoamine oxidase inhibitors increase brain concentrations of norepinephrine while imipramine-like agents potentiate the physiological effects of norepinephrine. Reserpine, a drug which can cause clinical depression, depletes catecholamines, but other amines may also be involved in its mechanism of action. A rigorous extrapolation from pharmacological studies to pathophysiology clearly cannot be made. Clinical studies relevant to the catecholamime hypothesis are limited and the findings are inconclusive. It is not possible, therefore, to confirm definitively or to reject the catecholamine hypothesis on the basis of data currently available. In our present state of knowledge, however, the catecholamine hypothesis is of considerable heuristic value, providing the investigator and the clinician with a frame of reference integrating much of our experience with those pharmacological agents which produce alterations in human affective states.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists
CARLSSON, A., LINDQVIST, M., & MAGNUSSON, T. (1957) · Nature · doi:10.1038/1801200a0 · Cited by 1,278
A CONCEPT FOR A ROLE OF SEROTONIN AND NOREPINEPHRINE AS CHEMICAL MEDIATORS IN THE BRAIN
Brodie, B. B., & Shore, P. A. (1957) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1957.tb40753.x · Cited by 637
POTENTIATION OF THE ANTIDEPRESSIVE EFFECT OF A MONOAMINE-OXIDASE INHIBITOR BY TRYPTOPHAN
Coppen, A., Shaw, D., & Farrell, J. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91084-5 · Cited by 344
Marley, E. (1962) · Psychopharmacologia · doi:10.1007/bf00411372 · Cited by 218
MODIFICATIONS OF THE PHARMACOLOGY OF RESERPINE AND SEROTONIN BY IPRONIAZID
Chessin, M., Kramer, E. R., & Scott, C. C. (1957) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11898-3 · Cited by 112
Achor, R. W. P. (1955) · JAMA · doi:10.1001/jama.1955.02960260011004 · Cited by 91
Potentiation of the behavioral effects of amphetamine by imipramine
Carlton, P. L. (1961) · Psychopharmacology · doi:10.1007/bf00404124 · Cited by 87
BUSFIELD, B. L., WECHSLER, H., & BARNUM, W. J. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710170050006 · Cited by 27
Research works printed but not linked: 10
- 10.1007/978-1-4684-8306-2_14 · doi:10.1007/978-1-4684-8306-2_14
- Axelrod J., 1963, : The Clinical Chemistry of Monoamines.
- 10.1016/S0079-6123(08)60119-3 · doi:10.1016/s0079-6123(08)60119-3
- Bergsman A., 1959, Acta Psychiat. Neurol. Scand. 33:suppl. 133
- Carlsson A., 1961, Neuropsychopharmacology, 2, 417
- 10.1016/S0079-6123(08)60110-7 · doi:10.1016/s0079-6123(08)60110-7
- Carlsson A., 1960, : Adrenergic Mechanisms.
- 10.1007/978-1-4684-8306-2_16 · doi:10.1007/978-1-4684-8306-2_16
- Cole, 1961, J. 0., Jones, R. T., and Kierman, C. L.: Drug Therapy, Progr. Neurol. Psychiat., 16, 539
- Cole, 1960, J. 0., Klerman, G. L., and Jones, R. T.: Drug Therapy, Progr. Neurol. Psychiat., 15, 540
Cited by
Items 201–251 of 251
An update on the role of glutamate in the pathophysiology of depression
Mitchell, N. D., & Baker, G. B. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01529.x · Cited by 91
Ketamine and the Future of Rapid-Acting Antidepressants
Riggs, L. M., & Gould, T. D. (2021) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072120-014126 · Cited by 87
Musazzi, L., Treccani, G., & Popoli, M. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00060 · Cited by 83
Neumeister, A., Drevets, W. C., Belfer, I., Luckenbaugh, D. A., Henry, S., Bonne, O., Herscovitch, P., Goldman, D., & Charney, D. S. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301010 · Cited by 85
GSK3β: a master player in depressive disorder pathogenesis and treatment responsiveness
Duda, P., Hajka, D., Wójcicka, O., Rakus, D., & Gizak, A. (2020) · Cells · doi:10.3390/cells9030727 · Cited by 84
“These findings resulted in the monoaminergic hypothesis of the MDD pathogenesis, which assumes that MDD is caused by a reduction in noradrenaline (NA) and serotonin (5-HT) neurotransmission [4].”
BackgroundTranslational neuroimaging: positron emission tomography studies of monoamine oxidase
Fowler, J. S., Logan, J., Volkow, N. D., & Wang, G.-J. (2005) · Molecular Imaging and Biology · doi:10.1007/s11307-005-0016-1 · Cited by 81
Pathobiological targets of depression
Chopra, K., Kumar, B., & Kuhad, A. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.553603 · Cited by 76
Velasco, F., Velasco, M., Jiménez, F., Velasco, A. L., & Salin-Pascual, R. (2005) · Neurosurgery · doi:10.1227/01.neu.0000172172.51818.51 · Cited by 75
Dilsaver, S. C., & Greden, J. F. (1984) · Brain Research Reviews · doi:10.1016/0165-0173(84)90028-6 · Cited by 73
Tyrosine for depression: a double-blind trial
Gelenberg, A. J., Wojcik, J. D., Falk, W. E., Baldessarini, R. J., Zeisel, S. H., Schoenfeld, D., & Mok, G. S. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90017-3 · Cited by 71
Familial orthostatic tachycardia due to norepinephrine transporter deficiency
ROBERTSON, D., FLATTEM, N., TELLIOGLU, T., CARSON, R., GARLAND, E., SHANNON, J. R., JORDAN, J., JACOB, G., BLAKELY, R. D., & BIAGGIONI, I. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03703.x · Cited by 64
Page, C. E., Epperson, C. N., Novick, A. M., Duffy, K. A., & Thompson, S. M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02625-2 · Cited by 80
“Before clinical depression was even known as MDD, it was hypothesized in the 1960s to arise from a de fi cit in monoamines, including norepinephrine, dopamine, and serotonin [1, 2].”
Sales, A. J., & Joca, S. R. L. (2016) · Acta Neuropsychiatrica · doi:10.1017/neu.2015.40 · Cited by 62
“The conventional antidepressants available act via monoaminergic mechanisms, mainly by inhibiting monoamine reuptake or its metabolism, thus increasing monoamine availability at the synaptic cleft (4,36,37).”
BackgroundMethodPringle, A., & Harmer, C. J. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.4/apringle · Cited by 61
Normann, C., Frase, S., Haug, V., von Wolff, G., Clark, K., Münzer, P., Dorner, A., Scholliers, J., Horn, M., Vo Van, T., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.008 · Cited by 56
Kerman, I. A., Bernard, R., Bunney, W. E., Jones, E. G., Schatzberg, A. F., Myers, R. M., Barchas, J. D., Akil, H., Watson, S. J., & Thompson, R. C. (2012) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00135 · Cited by 59
Cognitive abnormalities and hippocampal alterations in monoamine oxidase A and B knockout mice
Singh, C., Bortolato, M., Bali, N., Godar, S. C., Scott, A. L., Chen, K., Thompson, R. F., & Shih, J. C. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308037110 · Cited by 56
HCN Channel Targets for Novel Antidepressant Treatment
Ku, S. M., & Han, M.-H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0538-7 · Cited by 54
“(DA) contribute to the pathophysiology of depression [10].”
BackgroundAtypical antipsychotics in bipolar depression: Neurobiological basis and clinical implications
Brugue, E., & Vieta, E. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.014 · Cited by 54
Direct Alteration of a Specific Inhibitory Circuit of the Hippocampus by Antidepressants
Méndez, P., Pazienti, A., Szabó, G., & Bacci, A. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1720-12.2012 · Cited by 53
Cowen, P., Green, A., Grahame‐Smith, D., & Braddock, L. (1985) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1985.tb02717.x · Cited by 53
Lee, H.-J., Son, G.-H., & Geum, D. (2013) · Psychiatry Investigation · doi:10.4306/pi.2013.10.3.225 · Cited by 48
Effect of lithium on the physostigmine-induced behavioral syndrome and plasma cyclic GMP
Oppenheim, G., Ebstein, R. P., & Belmaker, R. H. (1979) · Journal of Psychiatric Research · doi:10.1016/0022-3956(79)90024-4 · Cited by 48
Szklany, K., Wopereis, H., de Waard, C., van Wageningen, T., An, R., van Limpt, K., Knol, J., Garssen, J., Knippels, L. M. J., Belzer, C., et al. (2020) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1576362 · Cited by 46
Forskolin-stimulated platelet adenylyl cyclase activity is lower in persons with major depression
Menninger, J. A., & Tabakoff, B. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00245-4 · Cited by 44
“The biogenic amine theory of depression as first enunciated in the 1960s (Schildkraut 1965) postulated that depression involves a deficit of noradrenergic activity in certain brain areas.”
BackgroundEngel, D. F., de Oliveira, J., Lopes, J. B., Santos, D. B., Moreira, E. L. G., Farina, M., Rodrigues, A. L. S., de Souza Brocardo, P., & de Bem, A. F. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.029 · Cited by 44
Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery
McArthur, R. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.004 · Cited by 42
Woo, H. I., Lim, S.-W., Myung, W., Kim, D. K., & Lee, S.-Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0123-0 · Cited by 42
Molecular and Cellular Mechanisms of Antidepressant Action
Sharp, T. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_216 · Cited by 36
Govoni, S., Racchi, M., Masoero, E., Zamboni, M., & Ferini-Strambi, L. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000801 · Cited by 35
Morgan, J. A., Olagunju, A. T., Corrigan, F., & Baune, B. T. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.058 · Cited by 34
Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864902 · Cited by 29
“To find effective therapeutic approaches, MDD has been investigated as a disease of monoamine deficiency over the last century, which coincided with an explosion of pharmaceutical agents targeting the system (5, 6).”
BackgroundWest, C. H. K., & Weiss, J. M. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000489 · Cited by 30
“…most of this attention was focused first on norepinephrine (NE), deriving from the 'catecholamine hypothesis of depression ' (Bunney & Davis, 1965 ; Schildkraut, 1965 ; Schildkraut & Kety, 1967), and subsequently on serotonin (5-HT), with the introduction of selective serotonin reuptake inhibitors…”
Heterotrimeric G Proteins: Insights into the Neurobiology of Mood Disorders
Gonzalez-Maeso, J., & Meana, J. (2006) · Current Neuropharmacology · doi:10.2174/157015906776359586 · Cited by 29
Role of Glial Cells in Neuronal Function, Mood Disorders, and Drug Addiction
Tizabi, Y., Getachew, B., Hauser, S. R., Tsytsarev, V., Manhães, A. C., & da Silva, V. D. A. (2024) · Brain Sciences · doi:10.3390/brainsci14060558 · Cited by 27
Grammatopoulos, D. K. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.013 · Cited by 26
Wierońska, J. M., & Pilc, A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.010 · Cited by 23
Golan, M., Schreiber, G., & Avissar, S. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168038 · Cited by 22
Quest for biomarkers of treatment-resistant depression: Shifting the paradigm toward risk
Smith, D. F. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00057 · Cited by 22
Li, C., Cao, F., Li, S., Huang, S., Li, W., & Abumaria, N. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00454 · Cited by 21
Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants
Verkhratsky, A., Parpura, V., Scuderi, C., & Li, B. (2021) · Advances in Neurobiology · doi:10.1007/978-3-030-77375-5_13 · Cited by 19
Yrondi, A., Aouizerate, B., El-Hage, W., Moliere, F., Thalamas, C., Delcourt, N., Sporer, M., Taib, S., Schmitt, L., Arlicot, N., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00326 · Cited by 19
Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413658 · Cited by 21
Kalkman, H. O. (2023) · Biomedicines · doi:10.3390/biomedicines11030806 · Cited by 18
Selective effects of simultaneous monoamine depletion on mood and emotional responsiveness
Hughes, J.-M., Matrenza, C., Kemp, A. H., Harrison, B. J., Liley, D., & Nathan, P. J. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003845 · Cited by 16
The biology of mental disorders: progress at last
Hyman, S. E. (2023) · Daedalus · doi:10.1162/daed_a_02038 · Cited by 15
Urinary Catecholamine Levels and Response to Group Cognitive Behaviour Therapy in Depression
Oei, T. P. S., Dingle, G. A., & McCarthy, M. (2010) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465810000093 · Cited by 12
The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics
Ahmed, M., Boileau, I., Le Foll, B., Carvalho, A. F., & Kloiber, S. (2022) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2021-1926 · Cited by 11
Towards a theory of mood function
Wong, M. Y. (2016) · Philosophical Psychology · doi:10.1080/09515089.2015.1024830 · Cited by 10
Treatment with carbamazepine may enhance α2-noradrenergic autoreceptor sensitivity
Dilsaver, S. C., Peck, J. A., Traumata, D., & Swan, A. C. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90198-m · Cited by 6
Senserrich, J., Castro, E., Florensa-Zanuy, E., Díaz, Á., Pazos, Á., Adell, A., Tzinia, A., & Pilar-Cuéllar, F. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00716-5 · Cited by 2
Metadata
- Authors
- SCHILDKRAUT, J. J.
- Venue
- American Journal of Psychiatry
- Published
- 1965-11
- Volume
- 122
- Issue
- 5
- Pages
- 509-522
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2072219714
- Cited by
- 3,492
- References
- 8
- FWCI
- 39.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.